Company intelligence / Profile preview

Acetylon Pharmaceuticals, Inc.

Boston, Massachusetts, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Phase 1

Overview

Acetylon's lead drug candidate ACY-1215 (rocilinostat) was well-tolerated in Phase 1a trials and advanced to Phase 1b trials in combination with Revlimid (lenalidomide) and Velcade (bortezomib) plus dexamethasone for multiple myeloma. Citarinostat (ACY-241) reached Phase 2 for multiple myeloma.

Therapeutic areas: ImmunologyHematologyOncologyNeurologyInfectious Diseases
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

2 assets

ricolinostat

Phase 1

Indications: Relapsed chronic lymphocytic leukemia, Multiple myeloma

1 more asset in the full pipeline.

Request access →

Partnerships

CelgeneThe Leukemia & Lymphoma Society

Beyond the preview

Go deeper on Acetylon Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acetylon Pharmaceuticals, Inc..

Explore the full profile